Page last updated: 2024-08-24

imiquimod and Cutaneous T-Cell Lymphoma

imiquimod has been researched along with Cutaneous T-Cell Lymphoma in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (55.56)	29.6817
2010's	2 (22.22)	24.3611
2020's	2 (22.22)	2.80

Authors

Authors	Studies
DeSimone, JA; DiLorenzo, A; Lindberg, MR	1
Bates, SE; Dana, AN; Del Guzzo, CA; Geskin, LJ; Kojadinovic, A; Langhoff, E; Newman, JC; Park, YA; Vinnakota, RR	1
Huen, AO; Rook, AH	1
Heald, P; Poligone, B	1
Junkins-Hopkins, JM; Rook, AH; Suchin, KR	1
Amerio, P; Benucci, R; Canzona, F; Cavalieri, R; Didona, B; Rienzo, O	1
Beyeler, M; Burg, G; Conrad, C; Dummer, R; Gilliet, M; Laine, E; Urosevic, M	1
Bohmeyer, J; Gellrich, S; Kremer, A; Luger, T; Muche, M; Nashan, D; Stadler, R; Sterry, W	1
Brown, VL; Coutts, I; Stavrakoglou, A	1

Reviews

2 review(s) available for imiquimod and Cutaneous T-Cell Lymphoma

Article	Year
Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Current opinion in oncology, 2014, Volume: 26, Issue:2 Topics: Aminoquinolines; Humans; Imiquimod; Lymphoma, T-Cell, Cutaneous; Oligodeoxyribonucleotides; Quinolinium Compounds; Skin Neoplasms; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9; Toll-Like Receptors	2014
Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard. Dermatologic clinics, 2010, Volume: 28, Issue:3 Topics: Aminoquinolines; Combined Modality Therapy; Cryotherapy; Histone Deacetylase Inhibitors; Humans; Imiquimod; Lasers, Excimer; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Photosensitizing Agents; PUVA Therapy; Stem Cell Transplantation; Therapies, Investigational	2010

Article

Year

Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma.

Current opinion in oncology, 2014, Volume: 26, Issue:2

Topics: Aminoquinolines; Humans; Imiquimod; Lymphoma, T-Cell, Cutaneous; Oligodeoxyribonucleotides; Quinolinium Compounds; Skin Neoplasms; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9; Toll-Like Receptors

2014

Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard.

Dermatologic clinics, 2010, Volume: 28, Issue:3

Topics: Aminoquinolines; Combined Modality Therapy; Cryotherapy; Histone Deacetylase Inhibitors; Humans; Imiquimod; Lasers, Excimer; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Photosensitizing Agents; PUVA Therapy; Stem Cell Transplantation; Therapies, Investigational

2010

Trials

1 trial(s) available for imiquimod and Cutaneous T-Cell Lymphoma

Article	Year
Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure. The oncologist, 2021, Volume: 26, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Agent Orange; Anti-Bacterial Agents; Humans; Imiquimod; Lymphoma, T-Cell, Cutaneous; Middle Aged; Skin Neoplasms; Veterans	2021

Other Studies

6 other study(ies) available for imiquimod and Cutaneous T-Cell Lymphoma

Article	Year
Cutaneous T-Cell Lymphoma Treatment: Case Series of Combination Therapy With Intralesional Injections of 5-Fluorouracil and Topical Imiquimod. Cutis, 2023, Volume: 111, Issue:1 Topics: Fluorouracil; Humans; Imiquimod; Injections, Intralesional; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms	2023
Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Archives of dermatology, 2002, Volume: 138, Issue:9 Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Biopsy, Needle; Female; Follow-Up Studies; Humans; Imiquimod; Immunohistochemistry; Lymphoma, T-Cell, Cutaneous; Middle Aged; Neoplasm Staging; Skin Neoplasms; Treatment Outcome	2002
Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). The British journal of dermatology, 2004, Volume: 150, Issue:6 Topics: Administration, Topical; Adult; Aminoquinolines; Antineoplastic Agents; Cytokines; Follow-Up Studies; Humans; Imiquimod; Interferon-gamma; Ki-1 Antigen; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms	2004
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. Journal of the National Cancer Institute, 2005, Aug-03, Volume: 97, Issue:15 Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Clinical Trials as Topic; Dendritic Cells; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imiquimod; Immunohistochemistry; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Microscopy, Confocal; Plasma Cells; Polymerase Chain Reaction; Skin Neoplasms	2005
Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003, Volume: 1, Issue:10 Topics: Adult; Aged; Aminoquinolines; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Humans; Imiquimod; Immunosuppressive Agents; Interferons; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prednisone; PUVA Therapy; Remission Induction; Skin; Skin Neoplasms; Tacrolimus; Tetrahydronaphthalenes; Time Factors; Treatment Outcome; Vincristine	2003
Successful treatment of primary cutaneous follicle centre lymphoma with topical 5% imiquimod. The British journal of dermatology, 2007, Volume: 157, Issue:3 Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Humans; Imiquimod; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin Neoplasms; Treatment Outcome	2007